Tolterodine Extended Release Is Efficacious in Continent and Incontinent Subjects with Overactive Bladder

Urology

Volumn 72, Issue 3, 2008, Pages 488-493

  Rovner, Eric S ^a   Rackley, Raymond ^b,c   Nitti, Victor W ^d   Wang, Joseph T ^e   Guan, Zhonghong ^e  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOLTERODINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RELEASE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; OVERACTIVE BLADDER; PRIORITY JOURNAL; URINE INCONTINENCE; XEROSTOMIA;

AGED; BENZHYDRYL COMPOUNDS; CRESOLS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; PLACEBOS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; URINATION;

EID: 50249085363     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.05.019     Document Type: Article

References (27)

1. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61 (2003) 37-49
2. Andersson K.E. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol 3 (2004) 46-53
3. Stewart W.F., Van Rooyen J.B., Cundiff G.W., et al. Prevalence and burden of overactive bladder in the United States. World J Urol 20 (2003) 327-336
4. Milsom I., Abrams P., Cardozo L., et al. How widespread are the symptoms of an overactive bladder and how are they managed?. A population-based prevalence study. BJU Int 87 (2001) 760-766
5. Coyne K.S., Payne C., Bhattacharyya S.K., et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 7 (2004) 455-463
6. Liberman J.N., Hunt T.L., Stewart W.F., et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 57 (2001) 1044-1050
7. Coyne K.S., Zhou Z., Bhattacharyya S.K., et al. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 92 (2003) 948-954
8. Elinoff V., Bavendam T., Glasser D.B., et al. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract 60 (2006) 745-751
9. Roberts R., Bavendam T., Glasser D.B., et al. Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. Int J Clin Pract 60 (2006) 752-758
10. van Kerrebroeck P., Kreder K., Jonas U., et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 57 (2001) 414-421
11. Siami P., Seidman L.S., and Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther 24 (2002) 616-628
12. Homma Y., and Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol 22 (2004) 251-256
13. Kelleher C.J., Reese P.R., Pleil A.M., et al. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 8 (2002) S608-S615
14. Coyne K.S., Matza L.S., and Thompson C.L. The responsiveness of the overactive bladder questionnaire (OAB-q). Qual Life Res 14 (2005) 849-855
15. Michel M.C., de la Rosette J.J., Piro M., et al. Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. Eur Urol 48 (2005) 110-115
16. Rackley R., Weiss J.P., Rovner E.S., et al. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 67 (2006) 731-736
17. Brewster-Jordan J.L., Guan Z., Green H.L., et al. Establishing the content validity of the Urinary Sensation Scale (USS) (2005) Presented at a meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 15-18; Washington, DC
18. Coyne K.S., Matza L., Thompson C., et al. A comparison of three approaches to analyze urinary urgency as a treatment outcome (2005) Presented at the 35th Annual Meeting of the International Continence Society; August 28-September 2; Montreal, Quebec, Canada
19. Coyne K.S., Matza L., Thompson C., et al. From an OAB patient perspective: health-related quality of life improves when frequency and urgency improve (2005) Presented at the 35th Annual Meeting of the International Continence Society; August 28-September 2; Montreal, Quebec, Canada
20. Stach-Lempinen B., Sintonen H., and Kujansuu E. The relationship between clinical parameters and health-related quality of life as measured by the 15 D in incontinent women before and after treatment. Acta Obstet Gynecol Scand 83 (2004) 983-988
21. Dmochowski R., Abrams P., Marschall-Kehrel D., et al. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol 51 (2007) 1054-1064
22. Kaplan S., Roehrborn C., Dmochowski R., et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 68 (2006) 328-332
23. MacDiarmid S., and Rosenberg M. Overactive bladder in women: symptom impact and treatment expectations. Curr Med Res Opin 21 (2005) 1413-1421
24. van der Vaart C.H., de Leeuw J.R., Roovers J.P., et al. The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int 90 (2002) 544-549
25. Irwin D.E., Milsom I., Kopp Z., et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 97 (2006) 96-100
26. Nuotio M., Tammela T.L., Luukkaala T., et al. Urgency and urge incontinence in an older population: ten-year changes and their association with mortality. Aging Clin Exp Res 14 (2002) 412-419
27. Hu T.W., Wagner T.H., Bentkover J.D., et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 63 (2004) 461-465